OKYO Pharma (OKYO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

OKYO · Stock Price

USD 1.62+0.17 (+11.72%)

Market Cap: $84.8M

Historical price data

Overview

OKYO Pharma is a UK-based, NASDAQ-listed biotech focused on developing novel treatments for ocular surface diseases, specifically Neuropathic Corneal Pain (NCP) and Dry Eye Disease (DED). Its core achievement is pioneering the clinical path for NCP, having received the first-ever FDA IND clearance to evaluate a drug specifically for this condition. The company's strategy centers on its lead asset, Urcosimod, a first-in-class chemerin receptor agonist designed using its MAP technology to combat rapid ocular washout. OKYO aims to address multi-billion dollar markets with high unmet need through a targeted, platform-based approach.

OphthalmologyPain

Technology Platform

Proprietary Membrane Anchored Peptide (MAP) platform that tethers lipidated peptide drugs to the ocular surface to enhance residence time, combat washout, and increase potency.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
OK-101 + Placebo	Dry Eye Disease	Phase 2
OK-101 0.05% + OK-101 0.1% + Placebo	Neuropathic Pain	Phase 2

Opportunities

OKYO has a first-mover opportunity to define and treat the high-unmet-need market of Neuropathic Corneal Pain (NCP), where no FDA-approved therapies exist.

In the multi-billion dollar Dry Eye Disease market, its novel chemerin receptor mechanism and MAP technology platform offer potential for differentiated efficacy, particularly in addressing ocular pain.

Risk Factors

The company faces extreme binary risk as its entire value hinges on the clinical success of a single asset, Urcosimod, in two unproven indications.

As a micro-cap, pre-revenue biotech, it carries significant financial risk, requiring further dilutive capital raises to advance trials.

In Dry Eye Disease, it must compete in a crowded market against well-established, well-funded competitors.

Competitive Landscape

In NCP, OKYO faces minimal direct clinical competition, competing primarily against off-label therapies. In Dry Eye Disease, the landscape is intensely competitive with established blockbuster drugs (Restasis, Xiidra) and multiple late-stage candidates. OKYO's differentiation lies in its novel chemerin receptor mechanism, potential impact on pain, and enhanced ocular residence from its MAP technology.

More companies in Small Molecule Drugs →More companies in United Kingdom →